SM-102: Precision Lipid Nanoparticle Component for mRNA Delivery

Executive Summary: SM-102 is a synthetic ionizable lipid critical for lipid nanoparticle (LNP) systems in mRNA vaccine development. It facilitates cellular uptake and endosomal escape of mRNA, improving delivery efficiency (Wang et al., DOI:10.1016/j.apsb.2021.11.021). SM-102 is insoluble in water and DMSO but highly soluble in ethanol (≥175.8 mg/mL) under standard lab conditions. APExBIO supplies SM-102 (SKU C1042) at ≥98% purity, validated by mass spectrometry and NMR (product page). Machine learning approaches have benchmarked SM-102's performance in LNP optimization, confirming its relevance in mRNA vaccine research. Proper storage at -20°C preserves compound integrity for experimental workflows.

Biological Rationale

Lipid nanoparticles (LNPs) are the leading platform for delivering mRNA in vaccines and therapeutics, due to their ability to encapsulate and protect mRNA from degradation (DOI:10.1016/j.apsb.2021.11.021). Ionizable lipids like SM-102 enable efficient delivery by forming complexes with negatively charged mRNA, facilitating entry into target cells. SM-102's structure—heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate—confers pH-responsive charge properties essential for endosomal escape. These features are critical for successful translation of the mRNA payload inside cells. SM-102-based LNPs have been instrumental in the rapid development of mRNA vaccines, including those against COVID-19 (source).

Mechanism of Action of SM-102

SM-102 is classified as an ionizable cationic lipid. At acidic pH, such as within endosomes, it becomes positively charged, promoting fusion with the endosomal membrane and facilitating release of mRNA into the cytoplasm (Wang et al., 2022). In a typical LNP formulation, SM-102 binds to mRNA via electrostatic interactions during nanoparticle assembly. Upon cellular uptake, LNPs are trafficked to endosomes, where the acidic environment protonates SM-102’s amine groups. This change destabilizes the endosomal membrane, promoting mRNA release. SM-102 is non-functional in neutral pH environments, minimizing off-target effects and toxicity. Its molecular weight is 710.18 g/mol. Solubility is high in ethanol (≥175.8 mg/mL), but negligible in DMSO or water (APExBIO).

Evidence & Benchmarks

• SM-102 is a validated LNP ionizable lipid in mRNA vaccine research, with performance benchmarked using machine learning on over 325 LNP-mRNA formulations (DOI:10.1016/j.apsb.2021.11.021).
• Animal studies show SM-102-based LNPs efficiently deliver mRNA, though with slightly lower IgG titers compared to DLin-MC3-DMA at equivalent N/P ratios (Wang et al., Table 3, DOI).
• SM-102-containing LNPs enable robust endosomal escape, confirmed by molecular modeling and in vivo results (DOI).
• Manufactured by APExBIO at ≥98% purity, with identity confirmed by mass spectrometry and NMR (APExBIO).
• Optimized storage at -20°C is required to maintain stability; long-term storage of solutions is not recommended (APExBIO).

For a systems biology perspective and predictive modeling advances, see "SM-102 in Lipid Nanoparticles: Systems Biology and Predictive Modeling"—this article extends the discussion to network-level effects and simulation-based design strategies.

Applications, Limits & Misconceptions

SM-102 is applicable in LNP formulation for mRNA vaccine development, gene therapy, and nucleic acid delivery studies. It is optimized for research use and not for diagnostic or therapeutic administration in humans. SM-102 supports high mRNA encapsulation efficiency and is compatible with other LNP excipients such as cholesterol, DSPC, and PEG-lipids. It is a key component in the formulation of COVID-19 mRNA vaccines (DOI).

Common Pitfalls or Misconceptions

• Not a standalone delivery reagent: SM-102 requires combination with other LNP constituents for functional mRNA delivery; it cannot encapsulate mRNA alone.
• Limited solubility profile: SM-102 is insoluble in DMSO and water, and should only be dissolved in ethanol for formulation work (APExBIO).
• Not for human therapeutic use: SM-102 from APExBIO is for research purposes only; clinical use requires regulatory-grade material.
• Stability constraints: SM-102 solutions degrade if stored long-term, and all materials must be kept at -20°C or below (APExBIO).
• Performance context-specific: LNP delivery efficiency is influenced by formulation ratios, mRNA sequence, and experimental conditions—direct translation between systems is not guaranteed (DOI).

This article clarifies the boundaries of SM-102 utility compared with "SM-102 (SKU C1042): Reliable Lipid Nanoparticles for mRNA Delivery", which focuses more on practical lab workflows, while this review provides mechanistic benchmarks and limitations.

Workflow Integration & Parameters

For LNP preparation, SM-102 should be dissolved in ethanol at concentrations up to 175.8 mg/mL. Typical LNP formulations include ionizable lipid:cholesterol:DSPC:PEG-lipid at molar ratios of 50:38.5:10:1.5 (DOI). The C1042 kit from APExBIO is shipped with blue ice and must be stored at -20°C. Mass spectrometry and NMR confirm purity and identity, ensuring reproducibility in research workflows (APExBIO). For more practical troubleshooting and assay reliability, refer to "Enhancing mRNA Delivery and Assay Reliability with SM-102"—this article extends the discussion by providing quantitative Q&A and scenario-driven guidance for experimentalists.

Conclusion & Outlook

SM-102 remains a leading ionizable lipid for LNP-mediated mRNA delivery in research settings. Its predictable physicochemical properties, robust performance benchmarks, and validated manufacturing from APExBIO make it a standard for mRNA vaccine lipid nanoparticle formulation. Ongoing research leverages computational modeling and machine learning to further optimize LNP systems, with SM-102 as a benchmark for future innovation (DOI).